To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationI would now like to turn the conference over to Vivian Cervantes, CORE Investor Relations. Please go ahead.Good day, and welcome to the Plus Therapeutics January 22, 2026, Business Update Conference Call. [Operator Instructions] Please note that this event is being recorded.Vivian Cervantes Thank you, Chloe. Good morning, and thank you for participating in today's conference call. Earlier this morning, the company released a business update and outline of progress in its REYOBIQ clinical program ...

Plus Therapeutics (NasdaqCM:PSTV) Update / briefing January 22, 2026 09:00 AM ET Company ParticipantsAndrew Sims - CFOMarc Hedrick - CEOVivian Cervantes - Head of Investor RelationsConference Call ParticipantsJason Kolbert - AnalystEdward Woo - AnalystSean Lee - AnalystOperatorGood day and welcome to the Plus Therapeutics January 22nd, 2026, Business Update Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star ke ...

Corporate Update January 2026 Power and precision in cancer radiotherapeutics NASDAQ: PSTV Cautionary Note Regarding Forward Looking Statements This presentation contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forward-looking statements m ...

Core Insights - Plus Therapeutics is focused on scaling up the commercialization of CNSide and preparing for pivotal trials of REYOBIQ in 2026 [2][6] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, developing targeted radiotherapeutics for challenging CNS cancers [10] - The company aims to enhance clinical outcomes through a combination of image-guided local beta radiation and targeted drug delivery [10] Clinical Programs - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed for CNS tumors, with potential advantages over existing therapies [6] - The REYOBIQ clinical program includes trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer [6][8] - The ReSPECT-LM trial is expected to report data in Q3 2026, while the ReSPECT-GBM trial aims to complete enrollment and align with the FDA on pivotal trial design by Q4 2026 [7] Financial Updates - The company recently completed a $15 million offering to support its core business areas and extend its cash runway through 2027 [2] - Plus Therapeutics aims to cover 150 million US lives under various commercial payor agreements and achieve over 1,250 tests per year in commercial orders [7] CNSide Diagnostics - CNSide Diagnostics, a subsidiary of Plus Therapeutics, develops proprietary tests to identify tumor cells in the CNS, improving management for patients with leptomeningeal metastases [9]

HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics’ management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Con ...

Market Overview - U.S. markets ended the week with mixed results, as major benchmarks showed modest declines while small-cap stocks outperformed, with the Russell 2000 achieving record highs [2][4] - The Dow Jones Industrial Average and S&P 500 experienced slight decreases, while the Nasdaq also slipped, indicating an uneven market rally [2][3] Sector Performance - Semiconductor and AI-related technology stocks, particularly Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC), contributed to market stability earlier in the week, with TSMC reporting a 35% increase in net profit, driven by strong AI demand [3][6] - Bank earnings from Goldman Sachs and Morgan Stanley supported trading, despite rising Treasury yields and modest increases in oil prices [3] Small-Cap Stocks - The Russell 2000's performance marked a significant outperformance streak against the S&P 500, a trend not seen since 2008, bolstered by strong economic indicators such as low initial jobless claims [4] Notable Stock Movements - Venus Concept Inc. saw its stock surge over 500% after Madryn Asset Management acquired a 91% stake, leading to increased trading volume and investor interest despite recent revenue declines [8] - J.B. Hunt Transport Services Inc. reported mixed Q4 results, with revenue of approximately $3.097 billion slightly missing expectations, while earnings per share of $1.90 exceeded forecasts [11] - Plus Therapeutics Inc. faced a stock decline after pricing a public offering to raise $15 million at a discounted price, impacting investor sentiment [12] Analyst Insights - Rocket Lab USA, Inc. received a rare downgrade from Loop Capital, citing valuation concerns and near-term execution risks, which led to a decline in its stock price [10]

Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum.Plus Therapeutics, Inc. (PSTV) surged 8.40% to close at $0.31 after announcing the pricing of its underwritten public offering. The company is issuing 39,473,684 units, each consisting of one share of common stock and one warrant, at $0.38 per unit. Gross proceeds are expected to total approximatel ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 350 points on Wednesday.The Dow traded down 0.55% to 48,922.97 while the NASDAQ declined 1.58% to 23,335.70. The S&P 500 also fell, dropping, 1.06% to 6,889.76.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsEnergy shares gained by 2% on Wednesday.In trading on Wednesday, information technology stocks dipped by 1.3%.Top HeadlineU.S. retail sales increa ...

Plus Therapeutics Inc. (NASDAQ:PSTV) stock is down during trading session on Wednesday following the company’s announcement of a public offering.The stock’s decline comes as the broader markets experienced a mixed session, with major indices like the S&P 500 and Nasdaq both closing lower on the previous trading day.The company priced its underwritten public offering at $0.38 per unit, consisting of one share of common stock and one warrant, aiming to raise approximately $15 million before expenses.PSTV stoc ...